secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001193125-24-138874
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Q1 2024: $223.8M cash, no CRS/ICANS in CABA-201 trials; clinical data at EULAR June
--------------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments of $223.8M as of March 31, 2024, down from $241.2M Dec 31, 2023; runway into H1 2026.
- R&D expense $22.0M (vs $12.4M YoY); G&A $6.1M (vs $4.5M YoY).
- No CRS or ICANS of any grade observed in first patients dosed in RESET-Myositis and RESET-SLE trials.
- Initial clinical data from first patients in myositis and SLE to be presented at EULAR 2024 Congress in June.
- FDA granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations for CABA-201 in myositis; Fast Track and Orphan for SSc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524138874/0001193125-24-138874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524138874/d106913d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-138874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer